IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Ketter, James

ASHKENAZI, et al.

Application Serial No. 09/903,640

Filed: July 11, 2001

For: SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC

ACIDS ENCODING THE SAME

EXPRESS MAIL LABEL NO. EV 765 978 214 US

DATE MAILED: AUGUST 15, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP — RCE Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

08/18/2006 BABRAHAT 60000069 801641 69903640 81 FC:1801 790.68 DA

\boxtimes	This sta	atement qualifie	s under 37 C.F.R. §1.97, subsection (b) because (check all that apply):			
		(1) than a	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d) OR			
		(2)	It is being filed within 3 months of entry of a national stage OR			
•		(3) merits	It is being filed before the mail date of the first Office Action on the			
		(4) of a re	OR It is being filed before the mailing of a first Office Action after the filing quest for continued examination under § 1.114.			
	filing d stage a action of	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:				
		a certification	as specified in §1.97(e) is provided below; or			
			20 as set forth in §1.17(p) is authorized below, enclosed, or included with f other papers filed together with this statement.			
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:					
	A.	a certification	as specified in §1.97(e) is completed below; and			
	B.	a petition unde submitted here	er 37 C.F.R. §1.97(d) requesting consideration of this statement is ewith; and			
	C.	a fee of \$130.6 the payment o	00 as set forth in $\S1.17(i)(1)$ is authorized below, enclosed, or included with f other papers filed together with this statement.			
\boxtimes	of \$0.0	0 and charge ar	the Commissioner is hereby authorized to charge the above-referenced fees by additional fees or credit any overpayment associated with this posit Account No. <u>08-1641 (Attorney's Docket No. 39780-).</u>			
			Respectfully submitted,			
Dated:	August	15, 2006	Ginger R. Dreger, Esq. Reg. No. 33,055			
HELL	ER EH	RMAN LLP	5			

275 Middlefield Road Menlo Park, California 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

Form PTO-1449			Attorney's Docket No. 39780-1618P2648							
INFORMATION DISCLOSURE STATEMENT				Applicant(s) ASHKENAZI, et al.						
(use several sheets if necessary)			Filing	Date: AUG 1 5 2006	N N N N N N N N N N N N N N N N N N N	Group Art Unit:				
	(use sei	rerai Srieets	s ii riecessary)	II S PATE	NT SOCUMENTS	\$ /	100	<u> </u>	 	
Examiner	Ref.	Date	Document No.	Name	TRABE		lass	Subclass	Filing Date	<u> </u>
Initials	No.	Date	Document No.						(if appropr	
	I			DEIGN DA	TENT DOCUMENT	<u> </u>			<u>L </u>	iden in the
Examiner	Ref.	Date	Document No.	Name	ILITI DOCUMENT		lass	Subclass	Transla	tion
Initials	No.	Date	Document No.	, wante		١	.000	000000	YES	NO
		-								
				071150	DOO! MENTO			<u> </u>		
			(in aludin		DOCUMENTS	nas atcl				
Examiner	Ref.	Title	(IIICIUUIII	y autiloi, titi	e, date, pertinent pa	ges, etc./				
Initials	No.									
·	1.	Abe, N., e	t al., "An Increased Hig	h-Mobility G	roup A2 Expression	Level is Associa	ated w	ith malignant	Phenotype	in
	'	Pancreation	c Exocrine Tissue," Br	J Cancer - <u>89</u>	<u>9(11):2104-9 (2003) A</u>	Abstract.		Du I II ama	4-1 420(C)	060.0
	2.	Ando, M., et al., "Selective Apoptosis of Natural Killer-Cell Tumours by I-Asparaginase," Br J Haematol., - 130(6):8 (2005) Abstract.								
	3.	Aust, G., et al., "Human Thyroid Carcinoma Cell Lines and Normal Thyrocytes: Expression and Regulation of Matri Metalloproteinase Inhibitor-1 Messenger-RNA and Protein," <i>Thyroid</i> - 7(5):713-24 (1997) Abstract.								
	4.	Barnes, V.L., et al., "Expression of Embryonic Fibronectin Isoform EIIIA Parallels Alpha-Smooth Muscle Actin in Maturing and Diseased Kidney," J Histochem Cytochem 47(6):787-98 (1999) Abstract.								
	5	Bea, S., et al., "BMI-1 Gene Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle Cell Lymphonas," Cancer Res 61(6):2409-12 (2001) Abstract.			antle					
,		Blaschke,	V., et al., "Rapid Quan	titation of Pro	oinflammatory and (Chemoattractant	Cytok	ine Expressi	on in Small 1	Tissue
	6.		- <u>246(1-2)</u> :79-90 (2000)		iis. Validation of a iv	ew iteal-fille iti	al-Time RT-PCR Technology," <i>J Immunol</i>			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	—	Buckley,	A.R., et al., "Butyrate-In	duced Rever	Reversal of Dexamethasone Resistance in Autonomouse Rat Nb2 Lymphoma					
	7.	Celis." Ap	optosis 2(6):518-28 (1997) Abstra	ct.					
	8.	Genetic A	o, L. et al.,"Alterations in imal Model of Depres	sion," <i>Neuro</i>	sci Lett <u>265(3)</u> :19 [,]	1-4 (1999) Abstra	ıct.			
	9.	Caberlotto, L., et al., "Neurokinin 1 Receptor and Relative Abundance of the Short and Long Isoforms in the Human Brain," Eur J Neurosci 17(9):1736-46 (2003) Abstract.								
	10.	Choi, D., et al., "Characterization of Cyclin D2 Expression in Human Endometrium," J Soc Gynecol Investig 9(1):41-6 (2002) Abstract.								
	11.	Couvelard, A., et al., "Human Chorionic Gonadotrophin Beta Expression in Malignant Barrett's Oesophagus," Virchows Arch 445(3):279-84 (2004) Abstract.								
	12.	Dagenais, A., et al., "Downregulation of EnaC Activity and Expression by TNF-Alpha in Alveolar Epithelial Cells," Am J Physio Lung Cell Mol Physiol 286(2):L301-11 (2004) Abstract.				' Am J.				
	13.	De Boer, (C.J., et al., " Involemen	of the CCNI	Ol Gene in Hairy Cell	l Leukemia," <i>Anr</i>	n Onco	ol <u>7(3)</u> :251-	6 (1996) Abs	tract.
	14.		F., et al., "Inhibin and A Reprod <u>6(8)</u> :743-9 (20			xpression in Hun	nan Pl	acental Cells	Cultured in	Vitro,"
	15.	Dong, Z.,	et al., "Expression of N	lembrane-Ty	pe Matrix Metallopro		d 6 in	Mouse Corn	eas Infected	with P.
		Aeruginos	sa," Invest Opthalmol \	is Sci - <u>42(13</u>	<u>3):3223- (2001) Absti</u>	ract.				

EXAMINER:	DATE CONSIDERED:			
	·			
EXAMINER: Initial if citation considered, whether or not the citation co conformance and not considered. Include a copy of this form with nex	nforms with MPEP 609. Draw a line through the citation if not in tommunication to applicant.			
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).				
SV 2227074 v1				

	Form PTO-1449	Attorney's Docket No. 39780-1618P2C48	Application Serial No. 09/903,640		
INFORMATIO	ON DISCLOSURE STATEMENT	Applicant(s)			
III ORIMATIC	711 DIOGEOGOILE 017 11 E	ASHKENAZI, et al.			
		Filing Date:	Group Art Unit:		
(use se	veral sheets if necessary)	July 11, 2001	1636		
		OTHER DOCUMENTS	ng against the second of the s		
	(including	author, title, date, pertinent pages, etc	g.)		
16.	Transcriptase-Polymerase Chain R	of Proliferative Activity in Colorectal C leaction (RT-PCR)," <i>Cancer Invest.</i> - 1	9(6):588-96 (2001) Abstract.		
17.	Equine Vet J 34(4):349-58 (2002)	Abstract.	nd Absorption in Equine Small Intestine,"		
18.	Implications for Th Cell Lineage Co	ommitment and Maintenance," <i>J Immi</i>	Differentially Expressed in Th1 and Th2 Cells: unol 168(7):3181-7 (2002) Abstract.		
19.	Vitreoretinopathy," Br J Opthalmol	Invading Cells Contribute to Vitreal C 85(4):461-70 (2001) Abstract.			
20.	Transporter 2 in the Rat Facial Nuc	leus after Axotomy," Neuroscience -	d NMDA) and of Glutamate Vesicular 136(1):147-60 (2005) Abstract.		
21.	Forsberg, H., et al., "Altered Levels Radic Res 24(6):451-9 (1996) Ab		Subjected to a Diabetic Environment," Free		
22.	Freyschuss, B., et al., "Induction o	f the Estrogen Receptor by Growth Hoytes," <i>Endocrinology</i> - <u>133(4)</u> :1548-54	ormone and Glucocorticoid Substitution in 4 (1993) Abstract.		
23.	Fu K et al. "Cyclin D1-Negative Mantle Cell Lymphoma: A Clinocopathologic Study Based on				
24.	Cycle," Biol Reprod 54(3):700-8 (1996) Abstract.	and Gene Expression During the Estrous		
25.	(2005) Abstract.		gnant Melanoma," <i>Melanoma Res.</i> - <u>15(1)</u> :15-20		
26.	Futcher, B., et al., "A Sampling of t	he Yeast Proteome," Mol Cell Biol., -	<u>19(11)</u> :7357-68 (1999) Abstract.		
27:	George, J., et al., "Pre-translational Regulation of Cytochrome P450 Genes is Responsible for Disease-Specific Changes of Individual P450 Enzymes Among Patients with Cirrhosis," <i>Biochem Pharmacol.</i> - 49(7):873-81 (1995) Abstract.				
28.	165(7):3985-91 (2000) Abstract.		ulation by Protein Kinase C-alpha," <i>J immunol.</i> -		
29.	Gnatenko, D.V., et al., "Transcript I Expression," Blood - 101(6):2285-9	3 (2003) Abstract.	croarray and Serial Analysis of Gene		
30.	Biol Chem 273(33):21161-8 (1998) Abstract.	roblastoma and Retinoblastoma Cell Lines," J		
31.	Goldenberg, R.C., et al., "Modulati Endocrinol 177(2):327-35 (2003)	on of Gap Junction Mediated Intercel Abstract.	lular Communication in TM3 Leydig Cells," J		
32.	Abstract.		," Acta Biochim Pol <u>50(4)</u> :1065-73 (2003)		
33.	Lines of the National Cancer Institu	ıte's Anticancer Drug Screen," <i>Clin C</i>	ropyrimidine Dehydrogenase Profiles of Cell ancer Res <u>7(4)</u> :999-1009 (2001) Abstract.		
34.	Grenback, E., et al., "Galanin Pituit	ary Adenomas," <i>Regul Pept,</i> - <u>117(2)</u> :	127-39 (2004) Abstract.		
35.	Non-Invasive and Invasive Bladder	Transitional Cell Carcinomas," Int J.	yte-Type Fatty Acid Binding Protein Correlate in Oncol <u>13(2)</u> :379-83 (1998) Abstract.		
36.		le of Macrophage Migration Inhibitory ı Xi Za Zhi - <u>25(6)</u> :337-40 (2002) Abstr	r Factor in Acute Respiratory Distress act.		

EXAMINER:	DATE CONSIDERED:	ĺ
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next of	orms with MPEP 609. Draw a line through the citation if not in communication to applicant.	ļ

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2227074 v1

Form PTO-1449		Form PTO-1449	Attorney's Docket No. 39780-1618P2C48	Application Serial No. 09/903,640	
	INFORMATION DISCLOSURE STATEMENT		Applicant(s)		
			ASHKENAZI, et al.		
			Filing Date:	Group Art Unit:	
	(use sev	reral sheets if necessary)	July 11, 2001	1636	
			OTHER DOCUMENTS	andra de la companya de la companya De la companya de la	
	· · · · · · · · · · · · · · · · · · ·		uthor, title, date, pertinent pages,		
	37.	Habu, Y., et al., "Restored Expression Hyperuricemia in the Rat Kidney," B		sporters rOAT1, rOAT3 and rOCT2 after	
		Hahn M.F. et al "Regulation of Cvi	ochrome P4501A1 in Teleosts: Su	stained Induction of CYP1A1 mRNA, Protein, and	
	38.	Catalytic Activity by 2,3,7,8-Tetrachl	orodibenzofuran in the Marine Fis	h Stenotomus Chrysops," <i>Toxicol Appl</i>	
		Pharmacol 127(2):187-98 (1994) At	ostract.		
	39.	Hahnel, R., et al., "Expression of the	PS2 Gene in Breast Tissues Asset	ssed by pS2-mRNA Analysis and pS2-Protein	
		Radioimmunoassay," Breast Cancer	e Enidermal Growth Factor Recen	tract. tor in Sustaining Neutrophil Inflammation in	
	40.	Severe Asthma," Clin Exp Allergy.	33(2):233-40 (2003) Abstract.	Castaning recursor processes and a second	
_	41.	Hassett, C., et al., "Human Hepatic N	licrosomal Epoxide Hydrolase: Co	mparative Analysis of Polymorphic Expression,"	
	41.	Arch Biochem Biophys 337(2):275	-83 (1997) Abstract.		
	42.	Holten-Andersen, M.N., et al., "Local	ization of Tissue Inhibitor of Meta	lloproteinases 1 (TIMP-1) in Human Colorectal	
		Huang VH of al "Tissue Plasming	nt J Cance, - <u>113(2)</u> :198-206 (2005) Abstract. Logen Activator Induced by Dengue Virus Infection of Human Endothelial Cells," J		
	43.	Med Virol 70(4):610-6 (2003) Abstra	ract.		
	44.	Huettner, P.C., et al., "Neu Oncogen	e Expression in Ovarian Tumors: A	A Quantitative Study," <i>Mod Pathol.</i> - <u>5(3)</u> :250-6	
	44.	(1992) Abstract.		the Callaboration with FIGH and	
	45.	Hui, P., et al., "Real-time Quantitative Immunohistochemistry," Leuk Lymp		antle Cell Lymphoma: Comparison with FISH and	
		Husain I et al "Flevation of Topoi	somerase I Messenger RNA. Prote	in, and Catalytic Activity in Human Tumors:	
٠	46.	Demonstration of Tumor-Type Spec	ificity and Implications for Cancer	Chemotherapy," Cancer Res <u>54(2)</u> :539-46	
		(1994) Abstract.			
	47.	Ihmann, T., et al., "High-level mRNA	Quantification of Proliferation Ma	rker pKi-67 is Correlated with Favorable	
		Prognosis in Colorectal Carcinoma,	J Cancer Res Clin Uncol 130(1)	Response in Transfected Human Embryonic	
	48.	Kidney Cells," Am J Physiol Cell Ph			
	49.	Jacquemin, E., et al., "Developmenta	al Regulation of Acidic Fibroblast	Growth Factor (aFGF) Expression in Bovine	
	49.	Retina," Int J Biol 37(3):417-23 (19	993) Abstract.		
	50.	Jaime, M., et al., "The p21 (Cip1) Pro CDC25A in Mice Regenerating Liver	itein, A Cyclin Inhibitor, Regulates	the Levels and the Intracellular Localization of	
		Janssens N et al "Alteration of Fr	izzled Expression in renal Cell Ca	rcinoma," <i>Tumour Biol.</i> - <u>25(4)</u> :161-71 (2004)	
	51.	Abstract.		· _	
	52.			Intigen Expression in Normal and Malignant	
	J2.	Human Tissues," Int J. Cancer - 92(6	6):856-60 (2001) Abstract.	204) '- the State - Discourter Fatal Dustration "	
	53.			CB1) in the Mouse Placenta: Fetal Protection,"	
	Biol Reprod 73(4):591-7 (2005) Ab Kammaori, M., et al., "Expression of 54. Progesterone Receptors, in Breast		Human Telomerase Reverse Tran	scriptase Gene and Protein, and of Estrogen amd	
			t Tumors: Preliminary Data from Neo-Adjuvant Chemotherapy," Int J Oncol.		
		27(5):1257-63 (2005) Abstract.			
	55.			Muscle Loss in Experimental Cancer Cachexi," Br	
		J Cancer - 93(7):774-80 (2005), Abst	n of Protessome Subunits in Skal	etal Muscle of Cancer Patients with Weight Loss,"	
	56.	Int J. Biochem Cell Biol 37(10):219	6-206 (2005) Abstract.	oral manage of carroot , another more monders and a	
F	EXAMINER:		DATE CONSIDERE	D:	
			•		

·	
EXAMINER: Initial if citation considered, whether or not the citation conf	orms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next of	communication to applicant.
*If an asterisk is placed beside the reference number, a copy is not provide	ded because the reference was previously cited by or submitted
	4 W W 4 4 4 AF HOO CAOO OF OF D CAOO

d to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2227074 v1

Form PTO-1449		Attorney's Docket No.	Application Serial No.	
		39780-1618P2C48	09/903,640	
INFORMATION DISCLOSURE STATEMENT		Applicant(s)	71 of al	
		ASHKENAZ		
		Filing Date:	Group Art Unit:	
(use	several sheets if necessary)	July 11, 2001	1636	
		OTHER DOCUMENTS thor, title, date, pertinent pages, etc.)		
	Kogo, H., et al., "Cell Type-Specific C Distinct mRNAs," J Biol Chem 279	Occurrence of Caveolin-1alpha and -1beta in t [24]:25574-81 (2004) Abstract.		
:	^{70.} 155:19-24 (1992) Abstract.	Growth Factor Expression in Ovarian Cancer,	•	
	 Subtypes 1-5 and Correlation with Re 92(2):175-86 (2005) Abstract. 	eptors in Primary Human Breast Cancer: Quar eceptor Protein Expression and Tumor Pathol	logy," Breast Cancer Res. Treat	
(DU. Leukemia Cells," Proteomics - 5(4):8	nd Proteomic Analysis of the Effect of CpG-O 94-906 (2005) Abstract.	<u></u>	
	Landmark, B.F., et al., "Cellular Loca Protein Kinase in Rat Testis," <i>J Repr</i>	tion and Age-dependent Changes of the regu od Fertil 99(2):323-34 (1993) Abstract.		
. (DZ. Immunohistochemistry Reveals Inter	of CK20 Gene and Protein Expression in Colo - and Intratumour Heterogeneity," <i>J Pathol</i>	198(2):198-206 (2002) Abstract.	
	Legrand, O., et al., "Expression of the Peripheral Blood and Bone Marrow H	e Multidrug Resistance-Associated Protein (N laemopoietic Cells," <i>Br J, Haematol.</i> - <u>94(1)</u> :2:	IRP) mRNA and Protein in Normal 3-33 (1996) Abstract.	
	105(21):2524-30 (2002) Abstract.	othelial Growth Factor Enhances Cardiac Allograft Arteriosclerosis," Circulation -		
(55. Experimental Acute Cerebral Ischem	ns of Arachidonic Acid-Sensitive Tandem-Por ia," <i>Biochem Biophys Res Commun.</i> - <u>327(4)</u>	:1163-9 (2005) Abstract.	
	66. Li, Y., et al., "Retinal Preconditioning 44(3):1299-304 (2003) Abstract.	and the Induction of Heat-Shock Protein 27,"	Invest Ophthalmol Vis Sci	
	Lindberg, P., et al., "Increasing Expre	ession of Tissue Plasminogen Activator and F essive Inflammation," <i>Arch Oral Biol.</i> - <u>46(1)</u> :2	Plasminogen Activator Inhibitor Type 23-31 (2001) Abstract.	
	Macabeo-Ong, M., et al., "Effect of De Reaction Analyses," 15(9):979-87 (20	uration of Fixation on Quantitative Reverse Tr	anscription Polymerase Chain	
	Maruyama, H., et al., "Id-1 and Id-2 at Pancreatitis." Am J Pathol 155(3):8	e Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic 15-22 (1999) Abstract.		
	70. Meehan, T.P., et al., "Tightly Regulate Cells." J Mol Endocrinol 32(1):247-	ed and Inducible Expression of a Yoked Hormone-Receptor Complex in HEK 293		
	Mendoza-Rodriguez, C.A., et al., "C-f	os and Estrogen Receptor Gene Expression Pattern in the Rat Uterine Epithelium		
	Meoni, P., et al., "[3H]MK-801 Binding	g and the mRNA for the NMDARI Subunit of the NMDA Receptor are Differentially rain," <i>Brain Res Mol Res.</i> - <u>54(1)</u> :13-23 (1998) Abstract.		
	73. Mezzano, S.A., et al., "Overexpression Membranous Nephropathy." Kinev Ir	on of Chemokines, Fibrogenic Cytokines, and ot 57(1):147-58 (2000) Abstract.	Myofibroblasts in Human	
	Mingrone, G., et al., "Decreased Unc. Obese Subjects," Obes Res 11(5):	oupling Protein Expression and Intramyocytic 632-40 (2003) Abstract.		
•	75. Miralles, C.P., et al., "Differential Exp	ression of the Short and Long Forms of the G Brain Res Mol Res 24(1-4):129-39 (1994) Ab	ostract.	
	76. Mizrachi, D., et al.,"Follicle-stimulation Boyine Cervix and Can Regulate Cer	g Hormone Receptor and Its Messenger Ribonucleic Acid are Present in the vical Prostanoid Synthesis," <i>Biol Reprod.</i> - 61(3):776-84 (1999) Abstract.		
	Monaghan, P., et al., "The Alpha(v)be	eta6 Integrin Receptor for Foot-and-Mouth Dis	ease Virus is Expressed	
	Constitutively on the Epithelial Cells	Targeted in Cattle," J Gen Virol 86(Pt 10):27	769-80 (2005) Abstract.	
EYAMINED:		DATE CONSIDERED:		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not	t in
conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or subm	itted

d to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2227074 v1

Form PTO-1449		Attorney's Docket No. 39780-1618P2C48	Application Serial No. 09/903,640	
INFORMATI	ON DISCLOSURE STATEMENT	Applicant(s)	ASHKENAZI, et al.	
(use se	veral sheets if necessary)	Filing Date: July 11, 2001	Group Art Unit: 1636	
	(including	OTHER DOCUMENTS author, title, date, pertinent pages, e	etc.)	
78.	Small Cell Lung Carcinoma," Int J	Cancer - 105(3):353-60 (2003) Abstra	n of Urokinase-Receptor Expression in Non act.	
79.	MMP, MMP-2 and MMP-9 in Human	Glioblastomas," <i>Int J Cancer</i> - <u>106(</u>	rrelates with Matrix Metalloproteinases MT1- 6):848-55 (2003) Abstract.	
80.	Esophageal Squamous Cell Carcin	omas," <i>Carcinogenesis</i> - <u>22(10)</u> :161	ession of the HLA Class I Genes in Human 5-23 (2001) Abstract.	
81.	Hum Pathol 34(7):639-45 (2003) A	Abstract.	f HER2/neu Oncogene in Synovial Sarcoma,"	
82.	Oberringer, M., et al., "Differential Tissue," Biochem Biophys Res Co	Expression of Heat Shock Protein 70 mmun 214(3):1009-14 (1995) Abstr	in Well Healing and Chronic Human Wound ract.	
83.	Orntoft, T.F., et al., "Genome-wide invasive and Invasive Human Tran	Study of Gene Copy Numbers, Transitional Cell Carcincomas," <i>Mol Cell</i>	scripts, and Proteins Levels in Pairs of Non- Proteomics 1(1):37-45 (2002) Abstract.	
84.	Orntoft, T.F., et al. "Genome-Wide Invasive and Invasive Human Tran	Study of Gene Copy Numbers, Trans sitional Cell Carcinomas," <i>Molecula</i>	scripts, and Protein Levels in Pairs of Non- r & Cellular Proteomics – <u>1</u> :37-45 (2002).	
85.	Pachmann, K., et al., "Expression by in Situ Amplification," Br J. Hae	of bcr-abl mRNA in Individual Chron matol - 112(3):749-59 (2001) Abstrac	ic Myelogenous Leukaemia Cells as determined t.	
86.	Pairon, J.C., et al., "Cell Localization and Regulation of Expression of Cytochrome P450 1A1 and 2B1 in Rat Lung af			
87.	Papotti, M., et al., "Correlative Imm	unohistochemical and Reverse Tran	nscriptase Polymerase Chain Reaction Analysis ng," <i>Diagn Mol Pathol.</i> - <u>9(1)</u> :47-57 (2000)	
88.	Papotti, M., et al., "Expression of Somatostatin Receptor Types 1-5 in 81 Cases if Gastrointestinal and Pancreatic Endocrine Tumors. A correlative Immunohistochemical and Reverse-Transcriptase Polymerase Chain Reaction Analysis," Virchows Arch 440(5):461-75 (2002) Abstract.			
89.	Paredes, J., et al., "P-Cadherin Ove is Associated with CDH3 Promoter	erexpression is an Indicator of Clinic Hypomethylation," <i>Clin Cancer R</i> es	cal Outcome in Invasive Breast Carcinomas and s 11(16):5869-77 (2005) Abstract.	
90.	Politis, I., et al., "Mammary-Derived Different Physiological States of the	d Growth Inhibitor Protein and Messone Gland," <i>J Dairy Sci.</i> - <u>75(6)</u> :1423-9	enger Ribonucleic Acid Concentrations in (1992) Abstract.	
91.	Preesman, A.H., et al., "T-Cell Reco	eptor V Beta-family Usage in Primary Dermatol 99(5):587-93 (1992) Abstr	Cutaneous and Primary Nodal T-cell non- act.	
92.	Pullig, O., et al., "Matrilin-3 in Hum Cartilage - 10(4):253-63 (2002) Abs	an Articular Cartilage: Increased Exp tract.	pression in Osteoarthritis," Osteoarthritis	
93.	Rey, C., et al., "Up-regulation of Mitochondrial Peripheral Benzodiazepine Receptor Expression by Tumor Necrosis			
94.	Rudlowski, C., et al., "GLUT1 Messenger RNA and Protein Induction Rrelates to the Malignant Transformation of			
95.	Sasaki, T., et al., "Expression and Tissues: An Immunochemical App	Distribution of Laminin Alpha1 and A roach," Exp Cell Res <u>275(2)</u> :189-99	Alpha2 Chains in Embryonic and Adult Mouse 9 (2002) Abstract.	
96.	Sedelies, K.A., et al., "Discordant F Biol Chem 279(25):26581-7 (2004	Regulation of Granzyme H and Granzyme B Expression in Human Lymphocytes," J		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation contonformance and not considered. Include a copy of this form with next of	forms with MPEP 609. Draw a line through the citation if not in communication to applicant.
*If an asterisk is placed beside the reference number, a copy is not provi PTO in a prior application that is identical in the statement and relied upon	ded because the reference was previously cited by or submitted to the
SV 2227074 v1	

Form PTO-1449		Form PTO-1449	Attorney's Docket No.	Application Serial No.	
			39780-1618P2C48	09/903,640	
INFORM	INFORMATION DISCLOSURE STATEMENT		Applicant(s)		
			ASHKENAZ		
,			Filing Date:	Group Art Unit:	
(us	se seve	eral sheets if necessary)	July 11, 2001	1636	
			OTHER DOCUMENTS		
		Shan V at al "BCL2 Protein Express	hor, title, date, pertinent pages, etc.) sion Parallels its mRNA level in normal and l	Maligent B Cells " Blood -	
	97.	104(9):2936-9 (2004) Abstract.	Sion Farancis its mixima lever in normal and	mangent b dens, blood	
		Shinohara, Y., et al., "Quantitative Det	erminations of the Steady Transcript Levels	of Hexokinase Isozymes and	
	98.	Glucose Transporter Isoforms in Norn	nal Rat Tissues and the Malignant Tumor Ce	II Line AH130," <i>Biochim Biophys Acta</i>	
		- 1368(1):129-36 (1998) Abstract.			
		Silvers, A.L., et al., "UVA Irradiation-In	duced Activation of Activator Protein-1 is C	orrelated with Induced Expression of	
ŀ	99.		Keratinocyte Cell Line HaCat," <i>Photochem F</i>	Photbiol <u>75(3)</u> :302-10 (2002)	
	_	Abstract.	A	Landa Afternal Callinion	
	100.		Aminopeptidase (aminopeptidase A): Molec	ular identity and Cellular	
	_	Localization," Am J. Physiol 267(4 P	<u>t 2):F546-57 (1994) Abstract.</u> Factor-Alpha Upregulates the Prostaglandi	n F2 FP1 Recentor Subtyne and the	
	101.	Cyclopygenase-2 leaform in Cultured	Amnion WISH Cells," <i>J Interferon Cytokine</i>	Res - 18(12):1039-44 (1998) Abstract.	
		Spike L et al "Transcriptional Activity	by of Potent Glucocorticoids: Relevance of C	Slucocorticord Receptor Isoforms and	
	102.		ty of Potent Glucocorticoids: Relevance of Glucocorticord Receptor Isoforms and op! Skin Physiol 16(3):143-50 (2003) Abstract.		
			n of AQP1 Water Channels in Isolated Rat In		
	103.	Interfering RNAs," J Biol Chem - 278(8	8):6268-74 (2003) Abstract.		
	404	Stearns, M.E., et al., "Type IV Collager	nase (M(r) 72,000) Expression in Human Pros	state: Benign and Malignant Tissue,"	
· _	104.	Cancer Res 53(4):878-83 (1993) Abst	tract.		
	105.		Detrusor III: Impact of Bladder Outlet Obstru		
	100.	Reticulum Protein and Gene Expression	on," J Urol 164(3Pt 2):1026-30 (2000) Abstr	act.	
	106.	Strickland, I., et al., "TNF-Alpha and IL	-8 are Upregulated in the Epidermis of Norm tion and E-Selectin Expression," <i>J Invest De</i>	nai Human Skin aπer UVB Exposure:	
		Correlation with Nuetrophii Accumula	wth Factor Expression is Increased in Huma	on Renal Fibrogenesis and May	
	107.		ration," <i>Kidney Int.</i> - <u>57(4)</u> :1521-38 (2000) Ab		
		Takahashi K et al "Adinosity Flevat	tes Plasma MCP-1 Levels Leading to the Inc	reased CD11b-Positive Monocytes in	
1	108.	Mice," J Biol. Chem 278(47):46654-6			
· · · · · · · · · · · · · · · · · · ·	400	Takimoto, Y., et al., "Augmented Expre	ession of Neuronal Nitric Oxide Synthase in	the Atria Parasympthetically	
	109.	Decreases Heart Rate During Acute M	yocardial Infarction in Rats," Circulation - <u>10</u>	<u>)5(4)</u> :490-6 (2002) Abstract.	
	110.	Telek, G., et al., "Differential Upregular	tion of Cellular Adhesion Molecules at the S	ites of Oxidative Stress in	
	110.	Experimental Acute Pancreatitis," J Se	urg Res 96(1):56-67 (2001) Abstract.		
	111.		ophy: An Unstable CTG Repeat in a Protein	Kınase Gene," Semin Cell Bıol	
	••••	6(1):13-9 (1995) Abstract.	2 Aldahada Dahadaanaanaa in Aha Marina I	Hanatoma Call Line Hone 4 by Various	
	112.		s 3 Aldehyde Dehydrogenase in the Mouse I	nepatoma Cen Line nepa-1 by various	
	Cnemicais, Chem Biol. Interact. • 03		etween Cyclin D1 and p21 (Waf1/Cip1) Durin	on Differentiation of Human Myeloid	
1	113. Leukemia Cell Lines," Leuk Res 27(12):1115-23 (2003) Abstract	ig Dirioi chilation of Haman myolola	
-		Van Reers F.H. et al. "Intestinal Carl	pamoyl Phosphate Synthase I in Human and	Rat. Expression during Development	
	114.	Shows Species Differences and Mosa	ic Expression in Duodenum of Both Species	," J Histochem Cytochem 46(2):231-	
		Shows Species Differences and Mosaic Expression in Duodenum of Both Species," <i>J Histochem Cytochem.</i> - 46(2):231-40 (1998) Abstract.			
- 1	Van Der Wilt, C.L., et al., "Expression		of Deoxycytidine Kinase in Leukaemic Cells	Compared with Solid Tumour Cell	
	115.	Lines, Liver Metastases and Normal L	iver," <i>Eur J Cancer</i> - <u>39(5)</u> :691-7 (2003) Abst	ract	
	116.		Cytokines and Growth Factors in Human Glomerulonephritides," Pediatr Nephrol		
		7(4):471-8 (1993) Abstract.			
EXAMINER:			DATE CONSIDERED:		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
conformance and not considered. Include a copy of this form with next communication to applicant.				
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the				
PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).				

SV 2227074 v1

Form PTO-1449		Attorney's Docket No. 39780-1618P2C48	Application Serial No. 09/903,640
INFORMATIO	N DISCLOSURE STATEMENT	Applicant(s)	
			SHKENAZI, et al.
		Filing Date:	Group Art Unit:
(use sev	eral sheets if necessary)	July 11, 2001	1636
			c.)
117.	Walmer, D.K., et al., "Malignant Transformation of the Human Endometrium is associated with Overexpression of Lactoferrin Messenger RNA and Protein," <i>Cancer Res.</i> - <u>55(5)</u> :1168-75 (1995) Abstract.		
118.	Wang, J., et al., "Cell Proliferation in Human Soft Tissue Tumors Correlates with Platelet-derived Growth Factor B Chain Expression: An Immunohistochemical and in Situ Hybridization Study," Cancer Res 54(2):560-4 (1994) Abstract.		
119.	Wang, J., et al., "Expression of Cadherins and Catenins in Paired Tumor and Non-neoplastic Primary Prostate Cultures and Corresponding Prostatectomy Specimens," <i>Urol Res.</i> - 28(5):308-15 (2000) Abstract.		
120.	Wang, L.G., et al., "Down-Regulation of Prostate-Specific Antigen Expression by Finasteride through Inhibition of Complex Formation Between Androgen Receptor and Steroid Receptor-binding Consensus in the Promoter of the PSA Gene in LNCaP Cells," Cancer Res 57(4):714-9 (1997) Abstract.		
121.	Weterman, M.A., et al., "Expression of Calcyclin in Human Melanocytic Lesions," Cancer Res <u>53(24)</u> :6061-6 (1993) Abstract.		
122.	Williams, E.T., et al., "Estrogen Regulation of the Cytochrome P450 3A Subfamily in Humans," J Pharmacol Exp Ther. 311(2):728-35 (2004) Abstract.		
123.	Wojtaszek, P.A., et al., "Severely Decreased MARCKS Expression Correlates with Ras Reversion but not with Mitogenic Responsiveness" Oncogene - 8(3):755-60 (1993) Abstract.		
124.	Zhong, W., et al., "Expression of Superoxide Dismutases, Catalase, and Glutathione Peroxidase in Glioma Cells," Free Radic Biol Med 27(11-12):1334-45 (1999) Abstract.		
125.	Xi, L., et al., "Expression of Human Telomerase Reverse Transcriptase in Cervix Cancer and its Significance," Zhonghua Fu Chan Ke Za Zhi - 40(6):407-10 (2005) Abstract.		
126.	Alborte B. et al. Molecular Biolog	y of the Cell (3rd ed. 1994) Cell 3rd at 4	153 Figure 9-2 of Cell 3rd Cell 3rd at 403
127.	Alberts, B., et al., Molecular Biology of the Cell (3 rd ed. 1994) Cell 3 rd at 453 Figure 9-2 of Cell 3 rd Cell 3 rd at 403 Alberts, B., et al., Molecular Biology of the Cell (4 rd ed.) In Cell 4 th , Figure 6-3 on page 302 Figure 6-90 on page 364 of		
128.	Aust, G., et al., "Human Throid Carcinoma Cell Lines and Normal Thyrocytes: Expression and Regulation of Matrix		
129.	Roa S. of at "RML1 Gone Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle		
130.	Beer et al. "Gene-expression profiles predict survival of patients with lung adenocarcinoma." Nature Biomedicine -		
131.	10.00 (40.00)		Cellular Biology - <u>19(11)</u> :7357-7368 (1999)
132.	Gnatenko, D.V. et al. "Transcript Profiling of Human Platelets Using Microarray and Serial Analysis of Gene		
133.	Greenbaum, D., et al., "Analysis of mRNA Expression and Protein Abundance Data: An Approach for the Comparison of the Enrichment of Features in the Cellular Population of Proteins and Transcripts," <i>Bioinformaticsl</i> - 18(4):585-496 (2002)		
134.	Gromova, I., et al., "Protein Abundancy and mRNA Levels of the Adipocyte-Type Fatty Acid Binding Protein Correlate in Non-Invasive and Invasive Bladder Transitional Cell Carcinomas," <i>International Journal of Oncology</i> - 13(2) 6 pages (1998)		
135.	Hähnel, E., et al., "Expression of the pS2 Gene in Breast Tissues Assessed by pS2-mRNA Analysis and pS2-Protein Radioimmunoassay," Breast Cancer Research and Treatment - 24:71-74 (1992)		

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
conformance and not considered. Include a copy of this form with next communication to applicant.				

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2227074 v1

Form PTO-1449		rm PTO-1449	Attorney's Docket No.	Application Serial No.		
INTO DIVATION DIGGI OCUDE CTATEMENT			39780-1618P2C48	09/903,640		
INFORMATION DISCLOSURE STATEMENT		DISCLOSURE STATEMENT	Applicant(s) ASHKENAZI, et al.			
	-		Filing Date:	Group Art Unit:		
(use several sheets if necessary)		ol chapte if nacessary)	July 11, 2001	1636		
[นิวิธ	36V616		THER DOCUMENTS			
(including author, title, date, pertinent pages, etc.)						
	400 H	Hirsch, F.R., et al., "Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology," Clinical Cancer Research - 7:5-22 (2001)				
1	136. R					
1	137. H	Holten-Andersen, M.D., et al., "Localization of Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) in Human Colorectal				
	A	denoma and Adenocarcinoma," Int.				
1			zled Expression in Renal Cell Carcinoma," 7			
1	139. P	Kammori, M., et al., "Expression of Human Telomerase Reverse Transcriptase Gene and Protein, and of Estrogen and Progesterone Receptors, in Breast Tumors: Preliminary Data from Neo-Adjuvant Chemotherapy", International Journal of Oncology - 27(5) (2005)				
1	^{140.} L	Kuo, C.C., et al., "A Transcriptomic and Proteomic Analysis of the Effect of CpG-ODN on Human THP-1 Monocytic Leukemia Cells," <i>Proteomics</i> - 5:894-906 (2005)				
1		Lewin, B., Genes VI (1997 <i>Genes VI</i> at 847-848				
1	142. 9	Meric, F., et al., "Translation Initiation in Cancer: A Novel Target for Therapy," Molecular Cancer Therapeutics - 1:971-979 (2002)				
1	^{143.} N	Munaut, C., et al., "Vascular Endothelial Growth Factor Expression Correlates With Matrix Metalloproteinases MT1-NMP, MNP-2 and NMP-9 in Human Glioblastomas," Int. J. Cancer - 106:848-855 (2003)				
1	^{144.} P	Maruyama, H., et al., "Id-1 and Id-2 are Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic Pancreatitis," American Journal of Pathology - 155(3):815-822 (1999)				
. 1	^{145.} H	Nuciforo, P. G., et al., "Molecular and Immunohistochemical Analysis of HER2/neu Oncogene in Synovial Sarcoma," Human Pathology - 34(7):639-645 (2003)				
. 1	146. o	Papotti, M., et al., "Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis of Somatostatin Receptor Type 2 in Neuroendocrine Tumors of the Lung," <i>Diagnostic Molecular Pathology</i> - 9(1):47-57 (2000)				
1	147. L	Walmer, D. K., et al., "Malignant Transformation of the Human Endometrium is Associated with Overexpression of Lactoferrin Messenger RNA and Protein," Cancer Research - 55(5):1168-1174 (1995)				
1	^{140.} a	Wang, J., et al., "Expression of Cadherins and Catenins in Paired Tumor and non-Neoplastic Primary Prostate Cultures and Corresponding Prostatectomy Specimens," <i>Urol Resl</i> - 28:308-315 (2000)				
1	149. Z	Zhigang, Z., et al., "Prostate Stem Cell Antigen (PSCA) Express in Human Prostate Cancer Tissues and its Potential Role in Prostate Carinogenesis and Progession of Prostate Cancer," World Journal of Surgical Oncology - 2-13 (2004)				
			<u>,</u>			
	_					
<u> </u>	-					
<u></u>						
	-		· · · · · · · · · · · · · · · · · · ·			
	-+	<u></u>				

EXAMINER:	DATE CONSIDERED:		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in			
conformance and not considered. Include a copy of this form with next communication to applicant.			

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2227074 v1